dPCR and qPCR Market is expected to reach US$ 18,230.74 million by 2030

Publisher: The Insight Partners

Digital PCR Segment, Based on Treatment, to Lead dPCR and qPCR Market During 2022–2030

According to our new research study on “dPCR and qPCR Market Forecast to 2030 – Global Analysis – by Treatment, Product, Application, End-User, and Geography,” the dPCR and qPCR market size was valued at US$ 8,976.99 million in 2022 and is projected to reach US$ 18,230.74 million by 2030; it is projected to register a CAGR of 9.3% from 2022 to 2030. Key factors driving the dPCR and qPCR market growth are the increasing incidence of genetic and infectious diseases, rising investments and funds for gene synthesis, and technological advancements in PCR technologies.

Based on treatment, the dPCR and qPCR market is bifurcated into quantitative PCR and digital PCR. The digital PCR segment held a larger market share in 2022 and is anticipated to register a higher CAGR in the market during 2022–2030. Digital PCR (dPCR) is a technique used to detect and quantify the amount of DNA or RNA present in a sample. dPCR is a highly precise method for detecting and quantifying nucleic acids that are both sensitive and repeatable. dPCR is an upgraded form of diagnostic technology for accurate nucleic acid measurement. In the dPCR process, the sample is partitioned into individual wells, and then amplification is carried out. Each partitioned sample acts as an individual reaction and, therefore, gives accurate and reliable results. The dPCR system sample partitioning allows for the sensitive, specific detection of single template molecules as well as precise quantification while mitigating the effects of target competition. This makes PCR amplification less susceptible to inhibition and dramatically improves the discriminatory capacity of assays that differ by only a single nucleotide.

To get free sample copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPHE100000817

dPCR offers benefits such as reduced error rate, less volume of reagents, lower experiment cost, and no reliance on standards and controls. Also, dPCR is highly quantitative as it does not depend on the relative fluorescence of the solution to determine the amount of amplified target DNA. dPCR is majorly used for the detection of genetic imbalances, or Copy Number Variant, sensitive mutant alleles in cancer diagnosis, and absolute quantification of viral pathogens. dPCR has several advantages over previous PCR procedures, including absolute quantification, increased sensitivity, and a more comprehensive dynamic range.

Many companies, such as Thermo Fisher Scientific Inc. and Bio-Rad Laboratories, Inc. offer various dPCR systems as well as kits and reagents for higher sensitivity, precision, and absolute quantification. In February 2023, Thermo Fisher Scientific Inc. introduced its new digital PCR research solution, the Applied Biosystems QuantStudio Absolute Q AutoRun dPCR suite. Furthermore, the increasing awareness of cutting-edge droplet digital PCR tests is projected to increase the application expansion. Thus, the benefits of digital PCR are expected to stimulate the growth of the segment during the forecast period.

Germany held the largest share in the European market in 2022. Germany is the biggest hub for biotechnology in Europe and worldwide owing to the presence of prominent biotech players, high-tech research labs, and massive funding for conducting research and development activities in the new areas of science and technology. The country has more biotechnology companies than any other country in Europe and is also among the toppers of the international list for a number of studies. The cutting-edge and high-quality research present in the country creates lucrative opportunities and the presence of an established market for dPCR and qPCR. Individual researchers, as well as academic universities in the country, are collaborating with international laboratories and institutions to create breakthrough innovations.

The rising funds and grants and increasing usage of synthetic biology in various application areas are the major factors for the growth of the dPCR and qPCR market. Additionally, the Government of Germany considers the formation of startups as an essential part of the development of the biotechnology industry in the country. For instance, BIO Deutschland is one such sector association of the German biotech industry based in Berlin, with over 330 members that promote and support the development of the German biotechnology sector to bloom as a robust economic entity. Similarly, Euronext is another organization that has succeeded in recognizing the current momentum of the biotech industry and assisting startups by creating jobs, raising funds and investments, and supporting the companies in various other ways. These initiatives are especially expected to benefit the SMEs in the life sciences sector in Germany over the forecast years.

Abbott Laboratories, Thermo Fisher Scientific Inc., Takara Bio Inc., Qiagen NV, Standard Biotools Inc., Lepu Medical Technology Beijing Co Ltd, F. Hoffmann-la Roche Ltd, Bio-rad Laboratories Inc, Agilent Technologies Inc, and Genome Diagnostics Pvt Ltd are among the leading companies operating in the dPCR and qPCR market.  

Based on treatment, the dPCR and qPCR market is bifurcated into quantitative PCR and digital PCR. In terms of product, the dPCR and qPCR market is segmented into reagents & consumables, instruments, and software & services. By application, the dPCR and qPCR market is segmented into research application, clinical application, and forensic application. In terms of end-user, the dPCR and qPCR market is segmented into hospitals and diagnostic centers, research laboratories and academic institutes, pharmaceutical and biotechnology companies, forensic laboratories, and clinical research organizations. The dPCR and qPCR market, by geography, is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of APAC), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of MEA), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Contact Us
Contact Person: The Insight Partners
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com